Pharmacokinetics of high-dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 6, 2002, Pages 648-659

  Muindi, Josephia R ^a   Peng, Yibing ^a   Potter, Douglas M ^a   Hershberger, Pamela A ^a   Tauch, Jil S ^a   Capozzoli, Mary Jo ^a   Egorin, Merrill J ^a   Johnson, Candace S ^a   Trump, Donald L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; PACLITAXEL; PROCHLORPERAZINE; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GROWTH INHIBITION; HEMATOLOGIC DISEASE; HUMAN; HYPERCALCEMIA; LYMPHOCYTOPENIA; MALE; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CALCITRIOL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY;

EID: 0036913420     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.129305     Document Type: Article

References (41)

1. 3-regulated expression of the eukaryotic genome. Nutr Rev 1994;52:376-82.
2. 3 and clinical applications. Bone 1995;17:107S-11S.
3. 3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology 1991;108:1083-86.
4. 3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem 1986;24:373-6.
5. Cross HS, Pavelka M, Slavik J, Peterlik M. Growth control of human colon cancer cells by vitamin D and calcium in vitro. J Natl Cancer Inst 1992;84:1355-7.
6. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-60.
7. 3 on primary cultures of human prostatic cells. Cancer Res 1994;54:805-10.
8. 3 analogue in a squamous cell carcinoma model system. Mol Cell Differ 1995;3:31-50.
9. 3. Cancer Res 1987;47:21-5.
10. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JR, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50:999-1006.
11. Johnson CS, McElwain MC, Light BW, Yu WD, Modzelewski RA, Trump DL, et al. Antiproliferative effects of vitamin D and its analogues in rodent tumor models. In: Norman AW, editor. Vitamin D: Chemistry, Biology and Clinical Applications. Riverside (CA): Univ. of California Printing;1997. p. 451-8.
12. Whitfield GK, Hsieh JC, Jurutka PW, Selnick SH, Haussler CA, MacDonald PN, et al. Genomic actions of 1, 25-dihydroxyvitamin D3. J Nutr 1995;125:1690S-4S.
13. Carlberg C. Mechanisms of nuclear signaling by vitamin D3: Interplay with retinoids and thyroid hormone signaling. Eur J Biochem 1995;231:517-27.
14. Haussler MR, Jurutka PW, Hseih JC, Thompson PD, Selznick SH, Haussler CA, et al. New understanding of the molecular mechanism of receptor-mediated genomic actions of vitamin D hormone. Bone 1995;17:33S-8S.
15. 3. Biochem J 1996;316:361-71.
16. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1, 25-Dihydroxycholecalciferol (1, 25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21 (Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59:2644-9.
17. Jiang H, Lin J, Su Z, Collart FR, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994;9:3397-406.
18. 3 leads to the induced differentiation of myelomonocytic cell line U937. Gene Dev 1996;10:142-53.
19. 3 in HL60 cells. Cancer Res 1996;56:264-7.
20. 3-induced apoptosis of murine squamous cell carcinoma cells: Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 2001;276:26365-73.
21. 3 are associated with enhanced activation of vitamin D receptor. J Biol Chem 1995;270:10551-8.
22. 3 and its analogues on the induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 1996;58:395-401.
23. Candeliere GA, Jurutka PW, Haussler MR, St-Arnaud R. A composite element binding vitamin D receptor, retinoid X receptor α and a member of the CTF/NF-1 family of transcription factor mediates the vitamin D responsiveness to the c-fos promoter. Mol Cell Biol 1996;16:584-92.
24. 3 enhances the expression of transforming growth factor β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 1995;55:1540-6.
25. Panichi V, DePietro S, Andreini B, Bianchi AM, Migliori M, Taccola D. Calcitriol modulates in vivo and in vitro cytokine production. A role for intracellular calcium. Kidney Int 1998;54:1463-9.
26. 3: In vivo and in vitro effects on human preleukemia and leukemic cells. Cancer Treat Rep 1985;69:1399-407.
27. Slapak CA, Desforges JF, Fogaren T, Miller KB. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea and calcitriol. Am J Hematol 1992;41:178-83.
28. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A phase I trial of calcitriol (1, 25-dihydroxycholecalciferal) in patients with advanced malignancy. Clin Cancer Res 1999;5:1339-45.
29. Davies M. High-dose vitamin D therapy. Indications, benefits and hazards. In: Walter P, Brubacher G, Stahelin H, editors. Elevated Dosages of Vitamins. Lewistown (NY): Hans Huber;1989. p. 81-6.
30. Trump DL, Hershberger PA, Modzelewski, RA, Bernardi RJ, Muindi J, Rueger RM, et al. Clinical development of calcitriol and calcitriol analogues as anticancer agents. In: Norman AW, Bouillon R, Thomasset M, editors. Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects. Riverside (CA): Univ. of California Printing; 2000. p. 469-75.
31. 3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 1998;90:134-41.
32. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997;57:3759-64.
33. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7:1043-51.
34. Tallarida RJ, Murray RB. In: Manual of Pharmacologic Calculation with Computer Programs. New York: Springer-Verlag; 1986. p. 197-291.
35. S-PLUS 2000. Seattle: MathSoft, Data Analysis Products Division; 2000.
36. 3 (calcitriol). J Urol 1998;159:2035-40.
37. Osborn JL. Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II trial of oral 1, 25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995;1:195-8.
38. Johnson CS, Egorin MJ, Zuhowski E, Parise R, Cappozolli M, Belani CP, et al. Effects of high dose calcitriol (1, 25 dihydroxyvitamin D3) on the pharmacokinetics of paclitaxel or carboplatin: Results of two phase I studies [abstract]. Proc Am Soc Clin Oncol 2000;19:210a.
39. Beer TM, Hough KM, Garzotto, Lowe BA, Henner WD. Weekly high dose calcitriol and docetaxel in advance prostate cancer. Semin Oncol 2001;28(Suppl 5):49-55.
40. Lemay J, Demers C, Hendy GN, Delvin EE, Gascon-Barre M. Expression of the 1, 25-dihydroxyvitamin D3-24-hydroxylase gene in rat intestine: Response to calcium, vitamin D3 and calcitriol administration in vivo. J Bone Miner Res 1995;10:1148-57.
41. Demers C, Lemay J, Hendy GN, Gascon-Barre M. Comparative in vivo expression of the calcitriol-24-hydroxylase gene in kidney and intestine. J Mol Endocrinol 1997;18:37-48.